<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288038</url>
  </required_header>
  <id_info>
    <org_study_id>SP-RE-003</org_study_id>
    <nct_id>NCT03288038</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy
      and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy
      in Patients with Primary Hypercholesterolemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2014</start_date>
  <completion_date type="Actual">November 19, 2015</completion_date>
  <primary_completion_date type="Actual">November 19, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline to 8 week in LDL-Cholesterol</measure>
    <time_frame>baseline and 8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 week in LDL-Cholesterol</measure>
    <time_frame>baseline and 4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the LDL-C level from the baseline to Week 4 and Week 8</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change and percent change in the levels of TC, TG, HDL-C, non-HDL-C, apolipoprotein B, and hs-CRP from the baseline to Week 4 and Week 8</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change and percent change in the ratios of LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I from the baseline to Week 4 and Week 8</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of the subjects who have reached the target LDL-C level according to the NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Week 4 and Week 8</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>RSV5mg + EZE 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 5mg/Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV10mg + EZE10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg/ Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV20mg + EZE10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg/Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>RSV5mg + EZE 10mg</arm_group_label>
    <arm_group_label>RSV5mg</arm_group_label>
    <arm_group_label>RSV10mg + EZE10mg</arm_group_label>
    <arm_group_label>RSV10mg</arm_group_label>
    <arm_group_label>RSV20mg + EZE10mg</arm_group_label>
    <arm_group_label>RSV20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <arm_group_label>RSV5mg + EZE 10mg</arm_group_label>
    <arm_group_label>RSV10mg + EZE10mg</arm_group_label>
    <arm_group_label>RSV20mg + EZE10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults aged 19 years or older

          2. Patients with primary hypercholesterolemia

          3. Patients who were informed about the purpose, method, effects, risks of this clinical
             study and have provided a written consent form signed by him/herself or by a
             representative

          4. those who show an LDL-C level of 250 mg/dL or below and a TG level of less than 350
             mg/dL at the run-in period (Week -1), and fall under the criterion of requiring the
             administration of antidyslipidemic drug of NCEP ATP III

        Exclusion Criteria:

          1. Patients with hypersensitivity to the investigational product or its ingredients

          2. Those with an uncontrolled hypertension (SBP ≧ 180 mmHg or DBP ≧ 100 mmHg)

          3. Those with a history of unstable angina, myocardial infarction, transient ischemic
             attack, cerebral vascular disease, coronary artery bypass or coronary intervention
             within 3 months of screening date

          4. Those with a history of malignant tumor within 5 years

          5. Those with a history of myopathy or rhabdomyolysis

          6. Those who show clinically significant confirmed laboratory test results (1) Patients
             showing AST or ALT level of greater than 2 times the institutional upper limit of
             normal or those with active liver disease or chronic hepatitis (2) A serum creatinine
             level greater than 2 times the institutional upper limit of normal (3) HbA1c &gt; 9% (4)
             Those with TSH level of greater than 1.5 times the institutional upper limit of normal
             (5) Those with CK level greater than 2 times the institutional upper limit of normal
             (However, except for an increase caused by a recent trauma, intramuscular injection or
             strenuous exercise)

          7. Those who were given, within 4 weeks prior to the baseline (8 weeks in case of
             fibrate) or are expected to be given during the study period, a drug that can have an
             effect on the efficacy assessment of the clinical study (eg: antidyslipidemic drug
             (statins, ezetimibe, fibrates, BAS, nicotinic acid and derivative, etc.), systemic
             glucocorticosteroids, steatolytic enzyme inhibitor, cyclosporine, HIV proteinase
             inhibitor, macrolide class antibiotics, etc.)

          8. Patients who were given estrogen within 3 months from the screening or those who are
             expected to be given an administration during the study period. (However, a patient
             who is under a hormone replacement therapy (HRT) will be allowed if no dose change is
             expected in the course of the clinical study.)

          9. Those with a history of alcohol or drug abuse

         10. Patients with a hereditary disorder of galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

         11. Pregnant or breast-feeding women

         12. Women of childbearing potential or men who do not intend to use an adequate
             contraceptive measure during the study period and for 4 weeks after the end of the
             study(Adequate contraception: Administration and transplantation of a progestin-only
             contraceptive pill, intrauterine device, condom, spermicidal agent, etc.)

         13. Patients who participated in another clinical study within 3 months from the screening
             date or have not had a washout period of at least 5 times the half-life of the active
             ingredient of the previously administered investigational product, whichever is longer

         14. Those with drug malabsorption

         15. Patients who has been judged by the investigator to be ineligible to participate in
             the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Hwaseong-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

